NanoMosaic Inc., a Boston, MA-based pioneer and leader in nanoneedle detection for proteomics and multi-omics applications, closed a $40.75m Series A financing.
The round was led by RA Capital Management, joined by Insight Partners, Pura Vida Investments, Time BioVentures and Tiger Gene.
The company intends to use the funds to expand its commercial infrastructure, further its application development efforts, and advance its collaborative diagnostic development programs.
Led by John Boyce, Co-Founder, Interim President and CEO, and Co-Founder of Tiger Gene, NanoMosaic is a biotechnology company which leverages nanoneedles, MosaicNeedles™, for protein detection and quantification to develop assays for biomarker discovery and validation. The NanoMosaic platform, Tessie™, provides an end-to-end solution that enables first of its kind protein interrogation and multi-omics analysis within a single chip on one run. The technology enables rapid, end user customization for assay development for proteomic and/or nucleic acid content.
The commercial launch for the company’s Tessie™ proteomic and multi-omics platform is targeted within Q1 2022.
NanoMosaic has installed Tessie™ systems at both Massachusetts General Hospital (MGH), as well as the New York Stem Cell Foundation (NYSCF). MGH has developed, and is validating, a diagnostic test for post-operative delirium on the Tessie™ system and has submitted its work to a high impact peer reviewed journal for publication.
FinSMEs
06/12/2021